anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Mural Oncology · conference-presentation

Alkermes | Investor Presentation Deck | 37 slides

37 pages · 3 arc beats · 2 loops

Conference-Presentation Download JSON
Unlock

Alkermes | Investor Presentation Deck | 37 slides

Mural Oncology · 2023-10
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

3
coverage by narrative range · generated from this deck JSON
Narrative range 13 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 2 slides 100% 2/2 slides 100% 2/2 slides · 10 hits
— 0/2 slides
— 0/2 slides
— 0/2 slides
100% 2/2 slides 100% 2/2 slides Solution 9 slides 100% 9/9 slides 100% 9/9 slides · 43 hits
— 0/9 slides
— 0/9 slides
55.6% 5/9 slides 100% 9/9 slides 11.1% 1/9 slides Financials 2 slides 100% 2/2 slides 100% 2/2 slides · 8 hits
— 0/2 slides
50% 1/2 slides 50% 1/2 slides 100% 2/2 slides
— 0/2 slides

Slide inventory

37
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
other
Open slide detail
03
front_matter
Open slide detail
04
transition
Open slide detail
05
The slide uses a numbered list format to present five key highlights about the company's spin-off status, cytokine portfolio, and specific drug program progresssummarize
Open slide detail
06
The slide uses a Gantt-style chart to map drug development stages across different indications.plan_implementation
Open slide detail
07
The slide lists names, titles, and previous company affiliations for both the Board and Management Team.introduce_nominees
Open slide detail
08
The diagram illustrates the interaction between T cells, tumor cells, and cytokines (IL-2, IL-12, IL-18) and the mechanism of checkpoint inhibitors.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
09
present_framework
Open slide detailBeat · ProblemLoop · Cost Of Inaction
10
The slide uses a problem-solution framework to justify the engineering approach for each therapeutic program.present_solution
Open slide detail
11
transition
Open slide detail
12
Uses a vertical process flow diagram to represent development stage gates.present_framework
Open slide detailBeat · Solution
13
Uses a before-after-framing style comparison to illustrate the mechanism of action differentiation.compare_peers
Open slide detailBeat · Solution
14
The chart displays longitudinal data for three cell types over 35 days, highlighting the differential pharmacodynamic response.analyze_data
Open slide detailBeat · Solution
15
The table uses a structured approach to categorize clinical trials into Foundational, Alternative Dosing, and Registrational enabling.present_framework
Open slide detailBeat · Solution
16
The slide uses a process flow diagram to illustrate the progression of the clinical trial cohorts.present_framework
Open slide detailBeat · Solution
17
The slide presents clinical trial safety data (ARTISTRY-1) comparing monotherapy and combination therapy cohorts.analyze_data
Open slide detailBeat · Solution
18
The slide uses a human body diagram to map clinical responses (CR, PR, uPR) by tumor type and treatment regimen.analyze_data
Open slide detailBeat · Solution
19
Includes a swimmer plot (onco-plot) and a summary table of best overall response (BOR) metrics.analyze_data
Open slide detailBeat · Solution
20
The slide uses a timeline to track treatment milestones and CT scans to show tumor reduction from baseline to complete response.illustrate_case
Open slide detailBeat · SolutionLoop · Before After
21
Includes a swimmer plot (left) and a summary table (right) with clinical trial metrics.analyze_data
Open slide detailLoop · Before After
22
The slide outlines a clinical trial protocol with three distinct cohorts and specific dosing schedules.present_framework
Open slide detail
23
Clinical trial design diagram showing randomization, arms, dosing schedules, and endpoints.present_framework
Open slide detail
24
The slide uses a hub-and-spoke diagram for the mechanistic combinations.present_solution
Open slide detail
25
The slide outlines the clinical strategy for optimizing nemvaleukin dosing, referencing specific clinical trials (ARTISTRY-3 and ARTISTRY-6).present_solution
Open slide detail
26
transition
Open slide detail
27
The slide uses a process diagram to show the IL-18 signaling cascade (IL-18 -> MYD88 -> IRAK -> NFkB -> IFNy) and a numbered list to detail its immunomodulatoryestablish_context
Open slide detail
28
Uses a combination of a scatter plot and biological mechanism diagrams to illustrate the inhibitory effect of IL-18BP.diagnose_problem
Open slide detail
29
Uses a before-after-bridge framework to illustrate the mechanism of action for the therapeutic candidate.propose_solution
Open slide detail
30
Data shows that while WT IL-18 is inhibited by IL-18BP, the variants are resistant to this inhibition.analyze_data
Open slide detail
31
The slide uses a diagram to illustrate the activation of immune cells (NKT, NK, CD4, CD8) by IL-12, leading to IFN-gamma production and subsequent downstream efdiagnose_problem
Open slide detail
32
The slide uses a process flow diagram to explain the therapeutic mechanism.present_solution
Open slide detail
33
Includes a bar chart showing dose-dependent PD response in a mouse model and a schematic of the split IL-12 mechanism.present_solution
Open slide detail
34
transition
Open slide detail
35
Includes a footnote regarding patient enrollment for clinical milestones.analyze_data
Open slide detailBeat · Financials
36
Uses a numbered list format to highlight key company facts.summarize
Open slide detailBeat · Financials
37
summarize
Open slide detail